The period for CME/CE credit for this activity has expired.

Diabetes

Type 2 Diabetes: Pathophysiologic Challenges, Incretin Solutions

INSTRUCTIONS

Click on the links below to view each section of the webcast for this activity. After viewing all 3 sections in their entirety, follow the link to take the posttest and evaluation.

After completing all 3 sections and the posttest and evaluation, a continuing education certificate will automatically be generated and should be printed or saved to your computer for your records.

Thank you for your participation.


CME/CE Information

CME Webcast Information

A CME webcast is a recorded version of a live symposium. This CME webcast is based upon educational content presented in a live symposium held in Miami, Florida on Saturday, December 8, 2007.

Release Date: February 2008

Expiration Date: February 28, 2009

Learning Format and Method of Participation

CME Webcast

To obtain CME credit, each participant should: 1) view the content presented; 2) complete and submit the CME demographic and evaluation form; 3) print the online CME certificate.

This activity should take approximately 1.5 hours to complete. The expiration date for this activity is February 28, 2009. No credit will be granted after this date.

Activity Overview

Incretin-based therapies not only offer the potential to address many of the pathophysiologic challenges of type 2 diabetes but also show great promise in addressing clinical challenges. This educational program will provide current information on pathophysiologic challenges in type 2 diabetes and potential solutions offered by incretin-based therapies.

Intended Audience

This activity is intended for endocrinologists, diabetologists, primary care physicians, and other diabetes healthcare professionals.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Describe the multiple metabolic defects that occur in type 2 diabetes
  • Explain the concept of the incretin effect, and describe defects in incretin secretion and action that occur in type 2 diabetes
  • Summarize the effects of GLP-1 and GLP-1 receptor agonists on metabolism
  • Discuss the clinical efficacy and safety of incretin-based therapies for the treatment of type 2 diabetes

CME Accreditation Statement

For Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Center for Accredited Healthcare Education (CAHE) and International Medical Press (IMP). CAHE is accredited by the ACCME to provide continuing medical education for physicians.

CAHE designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosures

In compliance with the ACCME, it is the policy of CAHE and IMP to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, CME provider staff, faculty, and planners) are expected to disclose any significant financial relationships with commercial interests over the past 12 months. CAHE and IMP also require that faculty identify and reference off-label product or investigational use of pharmaceutical agents and medical devices.

In accordance with ACCME Standards for Commercial Support, parallel documents from other accrediting bodies, CAHE and IMP policy, identification and resolution of conflicts of interest have been made in the form of external peer review of educational content. The following disclosures have been made:

F. Xavier Pi-Sunyer, MD, MPH

Formal Advisor: Amylin Pharmaceuticals, Eli Lilly and Company, McNeil Nutritionals, Novo Nordisk Inc, sanofi-aventis, Schering-Plough, Weight Watchers

Research Activities: Merck, Novartis, sanofi-aventis, Wrigley

Dr Pi-Sunyer discloses that he anticipates discussing investigational use of the following products in his presentation: liraglutide, vildagliptin, and exenatide LAR.

Derek LeRoith, MD, PhD

Speakers Bureau: Merck, Novo Nordisk Inc, Pfizer Inc, sanofi-aventis, Takeda Pharmaceutical Company Limited

Consultant: Pfizer Inc, sanofi-aventis

Dr LeRoith discloses that he does not anticipate referencing unlabeled/unapproved uses of drugs or products in his presentation.

CME Provider and Educational Partner Staff Disclosures

All staff of CAHE and IMP in a position to influence content have filed statements of disclosure with the CME provider. Any conflicts of interest were identified and resolved prior to their involvement in planning this activity.

Joelle Escoffery, PhD
Scientific Director, IMP
Conflict of Interest Disclosure: None

Amy Groves
Client Services Director, IMP
Conflict of Interest Disclosure: None

Robert Hash, MD
CME Peer Reviewer
Mercer University College of Medicine
Conflict of Interest Disclosure: None

Roger McCarter
Account Manager, IMP
Conflict of Interest Disclosure: None

Martin Quan, MD
CME Peer and Conflict of Interest Reviewer
Director of CME
David Geffen School of Medicine at UCLA
Conflict of Interest Disclosure: None

Steve Weinman, RN
Senior Director, CAHE
Conflict of Interest Disclosure: None

Commercial Support Acknowledgment

The content contained herein was derived from a regional meeting series originally supported by an educational grant from Novo Nordisk Inc.


Faculty Profiles


Picture of Derek LeRoith, MD, PhD

Derek LeRoith, MD, PhD
Professor of Medicine and Endocrinology
Chief, Division of Endocrinology, Diabetes, and Bone Disease
Mount Sinai School of Medicine
New York, New York

Derek LeRoith, MD, PhD, is Chief of the Division of Endocrinology, Diabetes, and Bone Disease, Department of Medicine, Mount Sinai School of Medicine. Dr LeRoith earned his MB ChB in 1967 and his PhD in 1973, both from the University of Cape Town in South Africa. He became a Fellow of the College of Physicians of South Africa in 1974 and a Member of the Royal College of Physicians in the United Kingdom in 1975.

Dr LeRoith is a recognized leader in the field of diabetes and endocrinology, having served as the Chief of the Diabetes Branch of the National Institutes of Diabetes, Digestive and Kidney Diseases from 1999 to 2005. He has also been a member of the National Board of Directors for the American Diabetes Association. He has authored over 500 publications in the area of endocrinology and has served on the editorial boards of numerous journals, including Growth Hormone & IGF Research, Diabetes/Metabolism Research and Reviews, and Endocrine Clinics of North America.


Pictur of F. Xavier Pi-Sunyer, MD, MPH

F. Xavier Pi-Sunyer, MD, MPH
Professor of Medicine
Columbia University College of Physicians and Surgeons

Professor of Applied Physiology
Columbia Teachers College

Senior Attending Physician
Chief, Division of Endocrinology, Diabetes, and Nutrition
St. Luke’s-Roosevelt Hospital Center

Director, New York Obesity Research Center
New York, New York

F. Xavier Pi-Sunyer, MD, MPH, is Professor of Medicine at the Columbia University College of Physicians and Surgeons and Professor of Applied Physiology at the Columbia Teachers College, Columbia University, both in New York City. At St. Luke's-Roosevelt Hospital Center in New York, he serves as Senior Attending Physician; Chief of the Division of Endocrinology, Diabetes, and Nutrition; and Director of the New York Obesity Research Center. Dr Pi-Sunyer is also Senior Attending Physician at New York-Presbyterian Hospital.

After receiving his BA in 1955 from Oberlin College in Ohio, Dr Pi-Sunyer went on to complete his MD from the College of Physicians and Surgeons at Columbia University in New York. In 1963, he was granted his MPH from Harvard University School of Public Health in Cambridge, Massachusetts.

A native of Barcelona, Spain, Dr Pi-Sunyer's distinguished career has expanded well past the borders of the US, beginning with his postdoctoral training, which took him to England and Nigeria with fellowships in the areas of research, medicine, and clinical nutrition. As a Fellow, invited speaker, Visiting Professor, and participant on numerous boards and task forces, he has worked in the Far East, Europe, Africa, and Latin America.

Dr Pi-Sunyer is a distinguished member of many national medical and scholastic societies. He has dedicated over 25 years of service to the American Diabetes Association, serving as President (1992-1993) and chairing numerous committees at the national, state, and local levels. In 1993, he was awarded the Banting Medal for Service from the American Diabetes Association.

Having contributed chapters to over 100 medical texts, Dr Pi-Sunyer is a prolific writer of articles for international peer-reviewed journals and the lay press. Since 1994, he has been the Associate Editor for the International Journal of Obesity and serves as a Journal Referee for over 20 professional journals.

 I have read and understand the CME Information indexed above.